Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Catalyst Pharmaceuticals Achieves 452nd Rank on Deloitte's 2024 Technology Fast 500 List with 234% Revenue Growth

Catalyst Pharmaceuticals ranked 452 on Deloitte's Technology Fast 500 for achieving 234% revenue growth from 2020 to 2023.Quiver AI SummaryCatalyst Pharmaceuticals, Inc. announced that it ranked number...

CPRX : 21.93 (+3.49%)
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

CPRX : 21.93 (+3.49%)
Insider Sale: Director at $CPRX (CPRX) Sells 72,500 Shares

PATRICK J MCENANY, a director at $CPRX ($CPRX), sold 72,500 shares of the company on 11-20-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.6% of their shares....

CPRX : 21.93 (+3.49%)
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CPRX : 21.93 (+3.49%)
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

CPRX : 21.93 (+3.49%)
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 58.58 (-0.76%)
TBPH : 9.24 (-2.43%)
MDGL : 336.74 (-2.45%)
LRMR : 6.18 (-2.37%)
CPRX : 21.93 (+3.49%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 58.58 (-0.76%)
TBPH : 9.24 (-2.43%)
MDGL : 336.74 (-2.45%)
LRMR : 6.18 (-2.37%)
CPRX : 21.93 (+3.49%)
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update

CPRX : 21.93 (+3.49%)
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

CPRX : 21.93 (+3.49%)
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...

BHVN : 47.28 (+4.53%)
ANIP : 57.86 (-1.33%)
CPRX : 21.93 (+3.49%)
SRRK : 37.06 (-1.75%)

Barchart Exclusives

This Dividend Stock Yielding 5% Hasn't Made Money for Buffett, But Could It Work for You?
Kraft-Heinz has not made money for Warren Buffett for almost a decade, since the merged entity started trading. Should you bet on the stock for its 5% dividend yield? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar